廣告
香港股市 已收市

  • 恒指

    17,763.03
    +16.12 (+0.09%)
     

  • 國指

    6,273.75
    -9.11 (-0.14%)
     

  • 上證綜指

    3,104.82
    -8.22 (-0.26%)
     

  • 滬深300

    3,604.39
    -19.52 (-0.54%)
     

  • 美元

    7.8209
    -0.0036 (-0.05%)
     

  • 人民幣

    0.9252
    +0.0016 (+0.17%)
     

  • 道指

    37,972.56
    -413.53 (-1.08%)
     

  • 標普 500

    5,065.46
    -50.71 (-0.99%)
     

  • 納指

    15,795.02
    -188.07 (-1.18%)
     

  • 日圓

    0.0494
    -0.0004 (-0.78%)
     

  • 歐元

    8.3518
    -0.0363 (-0.43%)
     

  • 英鎊

    9.7800
    -0.0480 (-0.49%)
     

  • 紐約期油

    81.52
    -1.11 (-1.34%)
     

  • 金價

    2,308.00
    -49.70 (-2.11%)
     

  • Bitcoin

    62,955.66
    -677.18 (-1.06%)
     

  • CMC Crypto 200

    1,290.55
    -48.51 (-3.62%)
     

Here's Why Lantheus Holdings (LNTH) is a Strong Momentum Stock

Zacks Equity Research
·2 分鐘文章

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals.

Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum.

Is This 1 Momentum Stock a Screaming Buy Right Now?

Different than value or growth investors, momentum-oriented investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

廣告

Lantheus Holdings (LNTH)

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes. It classifies its products into three categories — Precision Diagnostics (30.1% of FY23 revenues, up 9.4% from FY22), Radiopharmaceutical Oncology (65.9%, up 60.8%), and Strategic Partnerships and Other Revenue (4%, up 10.7%).

LNTH is a Zacks Rank #1 (Strong Buy) stock, with a Momentum Style Score of B and VGM Score of B. Shares are down 0.1% over the past one week and up 4.5% over the past four weeks. LNTH has lost 31.4% in the last one-year period as well. Looking at trading volume, an average of 752,869.06 shares exchanged hands over the last 20 trading days.

A company's earnings performance is important for momentum investors as well. For fiscal 2024, five analysts revised their earnings estimate higher in the last 60 days for LNTH, while the Zacks Consensus Estimate has increased $0.32 to $6.58 per share. LNTH also boasts an average earnings surprise of 14.8%.

With strong earnings growth, a good Zacks Rank, and top-tier Momentum and VGM Style Scores, investors should think about adding LNTH to their portfolios.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Lantheus Holdings, Inc. (LNTH) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research